Your browser doesn't support javascript.
loading
Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations.
Daniel, Anjali B; Saraff, Vrinda; Shaw, Nick J; Yates, Robert; Mughal, M Zulf; Padidela, Raja.
Afiliación
  • Daniel AB; Department of Paediatric Endocrinology & Metabolic Bone Diseases, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK.
  • Saraff V; Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK.
  • Shaw NJ; Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK.
  • Yates R; Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Mughal MZ; Department of Paediatric Intensive Care Unit, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK.
  • Padidela R; Department of Paediatric Endocrinology & Metabolic Bone Diseases, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK.
Orphanet J Rare Dis ; 13(1): 142, 2018 08 16.
Article en En | MEDLINE | ID: mdl-30115096
ABSTRACT

BACKGROUND:

Hypophosphatasia (HPP) is a rare, heterogeneous disease caused by low tissue-nonspecific alkaline phosphatase activity and associated with a range of signs and symptoms, including bone mineralization defects, respiratory problems, seizures, premature tooth loss, and fractures. Data from patients with HPP and their healthcare resource utilization are lacking. We evaluated healthcare utilization for 3 patients with differing severities of HPP.

RESULTS:

Patient 1 had perinatal HPP (received enzyme replacement therapy asfotase alfa under a compassionate use program), Patient 2 had infantile HPP, and Patient 3 had childhood HPP. Healthcare resources used in the National Health Service, England, were identified from coded activities in the hospital database and detailed medical records. These data showed that healthcare utilization was directly related to disease severity. Patient 1 had respiratory complications necessitating prolonged admission for ventilation from birth. Over 2.5 years, this patient was hospitalized 725 days, with visits from 16 specialists. Patient 2 had HPP-associated signs and symptoms starting in infancy, was treated for craniosynostosis, experienced multiple fractures, and required outpatient management for > 18 years. Patient 3 developed signs and symptoms of HPP in childhood and received outpatient and day case treatment for dental, orthopedic, and cardiovascular problems over 24 years. Healthcare utilization varied with severity and complexity of disease manifestations between these patients.

CONCLUSIONS:

With the recent approval of asfotase alfa for HPP, data from this analysis may help mobilize multidisciplinary healthcare resources for management of HPP by elucidating healthcare resource needs of patients who show a spectrum of clinical manifestations of HPP.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Inmunoglobulina G / Fosfatasa Alcalina / Hipofosfatasia Límite: Child, preschool / Female / Humans / Infant / Male / Newborn / Pregnancy Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Inmunoglobulina G / Fosfatasa Alcalina / Hipofosfatasia Límite: Child, preschool / Female / Humans / Infant / Male / Newborn / Pregnancy Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido